Furen Group Pharmaceutical Co.Ltd(600781)
Short form equity change report
Name of listed company: Furen Group Pharmaceutical Co.Ltd(600781) listing place: Shanghai Stock Exchange Stock abbreviation: St Furen Stock Code: 600781 information disclosure obligor: Shenzhen pingjiaxinyuan equity investment partnership (limited partnership) Address: 19a-08, building 1, China Phoenix building, Futian District, Shenzhen mailing address: 29th floor, Ping An financial center, 5033 Yitian Road, Futian District, Shenzhen nature of share change: decrease
Date of signature: February 21, 2022
Statement of information disclosure obligor
The words or abbreviations mentioned in this part have the same meanings as those mentioned in the “interpretation” of this report. 1、 The information disclosure obligor prepares this report in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies, the standards for the content and format of information disclosure by companies that publicly issue securities No. 15 – Report on changes in equity and other relevant laws, regulations and normative documents.
2、 The information disclosure obligor has obtained necessary authorization and approval for signing this report, and its performance does not violate or conflict with any provision in the articles of association or internal rules of the information disclosure obligor.
3、 In accordance with the provisions of the securities law of the people’s Republic of China and the measures for the administration of the acquisition of listed companies, this report has fully disclosed the changes in the shares of the information disclosure obligor in Furen pharmaceutical.
As of the signing date of this report, except for the information disclosed in this report, the information disclosure obligor has not increased or reduced its shares in Furen Pharmaceutical by any other means.
4、 The information disclosure obligor has not entrusted or authorized any other person to provide information not listed in this report and make any explanation or explanation to this report.
The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and will bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
catalogue
The disclosure obligor declares that Section 1 interpretation Section 2 introduction of information disclosure obligors 5 I. Basic information of information disclosure obligor 5 II. Basic information of the main person in charge of the information disclosure obligor 6 3. The information disclosure obligor holds more than 5% of the issued shares of other domestic and overseas listed companies Section III purpose of equity change Section IV equity change method 8 I. information disclosure obligors’ ownership of interests in listed companies before and after this equity change 8 II. Method of equity change this time 8 section V Trading of listed shares within the first six months Section 6 other major matters Section 7 documents for future reference 11 I. documents for future reference 11 II. Place for future reference 11. The disclosure obligor declares that 12. Attached table of short form equity change report thirteen
Section I interpretation
In this report, unless otherwise specified, the following abbreviations have the following meanings: Furen pharmaceutical, company and listed company refer to Furen Group Pharmaceutical Co.Ltd(600781)
The information disclosure obligor refers to Shenzhen pingjiaxinyuan equity investment partnership (limited partnership)
Furen Pharmaceutical Group Industrial Co., Ltd. issued shares and paid cash restructuring report refers to
Report on purchasing assets and raising supporting funds and related party transactions (Revised)
Listed company / Furen pharmaceutical refers to Furen Group Pharmaceutical Co.Ltd(600781)
Pingjiaxinyuan refers to Shenzhen pingjiaxinyuan equity investment partnership (limited partnership)
Ping Jiaxinyuan’s reduction of the previous equity change through the centralized bidding of Shanghai stock exchange refers to the behavior of holding less than 5% of the equity of listed companies due to the shares of municipal companies.
For this equity change, the report of Furen pharmaceutical collection issued by the information disclosure obligor refers to
Simplified equity change report of Tuan Pharmaceutical Co., Ltd
CSRC and CSRC refer to the China Securities Regulatory Commission
Shanghai Stock Exchange and stock exchange refer to Shanghai Stock Exchange
Company Law refers to the company law of the people’s Republic of China
Securities Law means the securities law of the people’s Republic of China
The standards for the contents and forms of information disclosure by public securities companies No. 15 refers to
——Equity change report
Listing Rules refers to the Listing Rules of Shanghai Stock Exchange (revised in 2020)
Yuan, 10000 yuan and 100 million yuan refer to RMB yuan, 10000 yuan and 100 million yuan
Section II introduction to information disclosure obligors
1、 Basic information of information disclosure obligor
(I) basic information
Company name: Shenzhen pingjiaxinyuan equity investment partnership (limited partnership)
Nature of Enterprise Limited Partnership
The capital contribution is 513 million yuan
Registered address: 19a-08, building 1, China Phoenix building, Futian District, Shenzhen
Main office location: 29th floor, Ping An financial center, 5033 Yitian Road, Futian District, Shenzhen
Shenzhen sidaoke Investment Co., Ltd
Executive partner
(appointed representative: Xia Xiaoli)
Date of establishment: October 28, 2013
Unified social credit code 914403000818781567
Equity investment in unlisted enterprises; Carry out equity investment and enterprise listing consulting services and investment and business scope
Information consultation; Economic information consultation; Enterprise management consulting
(II) property right control relationship
The structure of property right relationship is as follows:
2、 Basic information of the principal of the information disclosure obligor
Name: Xia Xiaoli
Gender male
ID No.: 4221271980********
Nationality China
Long term residence: Nanshan District, Shenzhen City, Guangdong Province
Have you obtained the right of residence in other countries or regions? No
The executive partner who works as an information disclosure obligor in the enterprise shall appoint a representative
3、 Information disclosure obligors hold more than 5% of the issued shares of other domestic and overseas listed companies
As of the date of signing this report, the information disclosure obligor does not hold more than 5% of the issued shares of other domestic and overseas listed companies.
This equity change is the reduction of Ping Jiaxin yuan’s holdings through the centralized bidding trading system of Shanghai Stock Exchange, resulting in the proportion of its shares reaching less than 5% of the total share capital of the listed company.
The purpose of the reduction of the information disclosure obligor is its capital demand.
In the next 12 months, the information disclosure obligor has a plan to reduce the shares of Furen pharmaceutical.
Section IV changes in equity
1、 Information disclosure obligors’ interests in listed companies before and after this equity change
Before this equity change, the information disclosure obligor directly held 33398147 shares of Furen pharmaceutical, accounting for 5.33% of the total share capital of Furen pharmaceutical.
After this equity change, the information disclosure obligor directly held 31298147 shares of Furen pharmaceutical, accounting for 4.99% of the total share capital of Furen pharmaceutical. 2、 Current equity change method
Ping Jiaxin yuan is sold through the centralized bidding trading system of Shanghai Stock Exchange.
Section V Trading of listed shares in the first six months
Within 6 months before the signing date of this report, the information disclosure obligor did not buy the shares of the listed company through the trading system of the stock exchange.
Section VI other major matters
As of the signing date of this report, the information disclosure obligor has truthfully disclosed the relevant information of this equity change in accordance with relevant regulations, and there is no other major information that should be disclosed in accordance with the application of law and in order to avoid misunderstanding of the content of this report.
Section VII documents for future reference
1、 Documents for future reference
(I) a copy of the legal person business license of the information disclosure obligor; 2、 Location for future reference
This report and documents for future reference are placed at the following places for investors to consult:
Furen Group Pharmaceutical Co.Ltd(600781)
No. 1, Congyuan Road, industrial cluster area, Luyi County, Henan Province
Statement of information disclosure obligor
I (and the organization I represent) promise that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal liabilities for its authenticity, accuracy and completeness. Information disclosure obligor (seal): executive partner of Shenzhen pingjiaxinyuan equity investment partnership (limited partnership) (seal): appointed representative of executive partner of Shenzhen sidaoke Investment Co., Ltd. (signature): Xia Xiaoli
Date: February 21, 2022
Attached table of simplified equity change report
Basic information
Name of listed company Furen Pharmaceutical Group Pharmaceutical Co., Ltd. is located in Luyi County, Henan Province
Limited company
Stock abbreviation: St Furen Stock Code: 600781
Name of information disclosure obligor: Shenzhen pingjiaxinyuan equity investment information disclosure obligor: 19a-08, building 1, huanghuang building, China Phoenix partnership (limited partnership), Futian District, Shenzhen
The number of shares with interests increases □ decreases √ whether there are persons acting in concert or not
Change of shareholding □□√
Is the information disclosure obligor an information disclosure obligor
The largest shareholder of the listed company yes □ no √ whether it is a listed company yes □ no √
Actual controller
Centralized trading through stock exchange √ agreement transfer □
Method of equity change (multiple choices) administrative transfer or change of state-owned shares □ indirect transfer □
New shares issued by listed companies □ execution of court ruling □
Inheritance □ gift □ others □ (please specify)
Type of stock before disclosure by the information disclosure obligor: A-share common stock number of shares with interests and number of shares held: 33398147 shares, accounting for the issued shares of the listed company
Shareholding ratio: 5.33%
After this equity change, the type of information stock: A-share common stock, the number of changes in the rights and interests of the disclosure obligor: 2100000 shares and change proportion, change proportion: 0.34% whether the information disclosure obligor intends to
Continue to decrease in the next 12 months yes √ no □
Holding information disclosure obligor before
6 months in the secondary market yes √ no □
Where the trading of shares of the listed company involves the reduction of shares held by the controlling shareholder or actual controller of the listed company, the information disclosure obligor shall also explain the following contents:
Controlling shareholder or actual controller
Is there any infringement during the reduction
Question on the rights and interests of the company and shareholders in the city √□
Title: controlling shareholder or actual shareholder
